Greater use of small molecule biomarkers in drug development is needed to transform efficiency and success rates, by driving deeper understanding of how non-genetic factors influence disease pathobiology and drug responsiveness.
In this session, Sapient will discuss how its next-generation rapid liquid chromatography-mass spectrometry systems enable untargeted small molecule biomarker discovery at unprecedented speed and at population scale, with the ability to assay >11,000 circulating factors per biosample in <1 minute per sample run.
During this talk we discuss:
- How Sapient systems enable a new scale of biomarker discovery
- 4D chemical characterization of known and unknown molecules
- Rapid biomarker cross-validation